Table 2 Differential serum metabolites among LG BC patients and HG BC patients as well as healthy controls.

From: Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer

No.

tR (min)

m/za

Formula

Metabolitesb

LGBC/healthy

HGBC/healthy

VIPe

p valuef

FCg

VIP

p value

FC

1

0.66

296.0661

C8H14N3O7P

5-Aminoimidazole ribonucleotidec

1.52

2.04 × 10−10

1.63

1.81

9.38 × 10−24

2.19

2

0.70

258.1050

C10H15N3O5

5-Methylcytidined

1.64

1.51 × 10−12

1.48

1.44

2.03 × 10−11

1.51

3

1.02

137.0457

C5H4N4O

Hypoxanthined

1.23

1.15 × 10−6

1.45

1.54

7.02 × 10−13

1.96

4

1.05

215.0160*

C6H8O7

Citric acidd

1.57

9.64 × 10−6

0.72

1.16

7.04 × 10−12

0.57

5

1.44

269.0880

C10H12N4O5

Inosined

1.60

8.66 × 10−12

1.79

1.67

3.48 × 10−17

2.72

6

2.24

209.0917

C10H12N2O3

Kynurenined

1.83

1.59 × 10−17

1.61

1.73

1.02 × 10−18

1.64

7

4.82

180.0651

C9H9NO3

Hippuric acidd

1.10

2.45 × 10−5

0.68

0.94

8.07 × 10−4

0.74

8

4.83

265.1182

C13H16N2O4

Acetyl-N-formyl-5-methoxykynurenamined

1.15

8.24 × 10−6

1.61

1.78

1.62 × 10−18

2.28

9

5.67

304.2112

C15H29NO5

3-hydroxyoctanoyl carnitinec

1.48

9.93 × 10−10

2.13

1.43

3.03 × 10−9

1.57

10

6.01

206.0806

C11H11NO3

Indolelactic acidd

1.49

5.25 × 10−10

1.60

1.78

6.37 × 10−18

2.14

11

6.34

286.2011

C15H27NO4

2-Octenoylcarnitinec

1.43

5.62 × 10−9

1.74

1.49

9.10 × 10−12

1.91

12

6.63

176.0697

C10H9NO2

Indoleacetic acidd

1.41

1.06 × 10−8

1.58

1.69

3.15 × 10−17

2.54

13

6.91

332.2428

C17H33NO5

3-hydroxydecanoyl carnitinec

1.85

1.62 × 10−18

2.18

1.47

1.45 × 10−10

1.67

14

6.93

288.2168

C15H29NO4

Octanoylcarnitined

1.53

1.55 × 10−10

1.48

1.04

2.98 × 10−5

1.51

15

7.58

314.2325

C17H31NO4

9-Decenoylcarnitinec

1.79

3.06 × 10−16

1.66

1.50

7.72 × 10−11

1.80

16

7.80

466.3159

C26H43NO6

Glycocholic acidd

1.02

1.01 × 10−4

1.68

1.60

1.79 × 10−13

2.34

17

7.97

316.2482

C17H33NO4

Decanoylcarnitined

1.47

1.67 × 10−9

1.54

1.07

2.27 × 10−5

1.57

18

8.09

512.3345

C24H50NO8P

PS(O-18:0/0:0)c

1.62

2.78 × 10−12

1.59

1.74

8.93 × 10−20

2.15

19

8.39

318.3003

C18H39NO3

Phytosphingosined

0.98

1.58 × 10−4

1.33

1.51

8.99 × 10−13

1.87

20

9.23

302.3052

C18H39NO2

Sphinganined

1.49

8.04 × 10−10

1.44

1.77

2.67 × 10−20

1.98

21

9.85

422.3263

C25H43NO4

linolenyl carnitinec

1.79

2.60 × 10−16

1.81

1.62

2.14 × 10−15

2.51

22

10.26

526.2934

C27H44NO7P

LysoPE(22:6/0:0)c

1.37

3.91 × 10−8

0.67

1.29

4.85 × 10−8

0.69

23

10.27

520.3406

C26H50NO7P

LysoPC(18:2)d

1.61

5.18 × 10−12

1.34

1.74

2.82 × 10−20

1.61

24

12.18

456.4043

C27H53NO4

Arachidyl carnitinec

1.56

4.47 × 10−11

1.35

1.61

5.23 × 10−14

1.53

25

12.23

550.3860

C28H56NO7P

LysoPC(20:1)c

1.79

2.64 × 10−16

1.78

1.61

1.77 × 10−13

1.51

26

13.44

552.4028

C28H58NO7P

LysoPC(20:0)d

1.41

1.07 × 10−8

1.53

1.60

6.09 × 10−15

2.05

  1. aThe ion marked were “*“ were [M + Na]+ and other ion were [M + H]+. bThe metabolites marked with “c” were putatively annotated, the metabolites marked with “d” were structurally identified by reference standards, and those in italic type were identified as differential metabolites that are common to both LG BC/HC and HG BC/HC. eVariable importance in the projection (VIP) was obtained from the OPLS-DA model. fThe p value was calculated from Student’s t test. gFold change was calculated from the normalized peak area between LG BC group vs HC group or between HG BC group vs HC group.
Back to article page